Z, H., H, C., C, L., X, T., L, J., F, X., . . . Y, Z. PD(L)1 Inhibitors Plus Lenvatinib Vs Atezolizumab Plus Bevacizumab Combined With HAIC for Unresectable HCC: A Propensity Score Matching Study. Dove Medical Press.
Chicago Style (17th ed.) CitationZ, He, Chen H, Liang C, Tang X, Jiang L, Xie F, Liu Q, and Zheng Y. PD(L)1 Inhibitors Plus Lenvatinib Vs Atezolizumab Plus Bevacizumab Combined With HAIC for Unresectable HCC: A Propensity Score Matching Study. Dove Medical Press.
MLA (9th ed.) CitationZ, He, et al. PD(L)1 Inhibitors Plus Lenvatinib Vs Atezolizumab Plus Bevacizumab Combined With HAIC for Unresectable HCC: A Propensity Score Matching Study. Dove Medical Press.
Warning: These citations may not always be 100% accurate.